Skip to main content

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis

 


A primary driver for this market is the worldwide increase in occurrence of diabetes and cancer, across all age groups. According to the World Health Organization (WHO) 2018 statistics, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. Moreover according to the World Health Organization cancer factsheet 2018, Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018.  Furthermore, increasing old age population is another driver, which is anticipated to create a high growth scenario for the market. As per the World Population Prospects 2019 revision, the number of people aged 80 years or over is projected to be triple, from 143 million in 2019 to 426 million in 2050.

Alternatively, factors restraining the market are complications and risks associated with the treatment including diarrhea, nausea, hair loss, vomiting, severe infections, infertility, and heart complications. 

Increasing prevalence of cancer will drive the overall autologous stem cell and non-stem cell based therapies market

According to a report by National Cancer Institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. alone. Moreover, it was also noted that around 595,690 people died from the disease in the same year. Autologous stem cell and non-stem cell based therapies is likely to become one of the preferred treatment for cancer. As the prevalence of cancer is rising at a considerable rate, the market is likely to grow during the forecast period.

North America, followed by Europe accounted for the major share of the autologous stem cell and non-stem cell based therapies market. This is due to minimization of risks related with the treatment. Moreover, the demand for these treatments is high due to their ability to cure a significant number of infectious diseases. Autologous stem cell and non-stem cell based therapies do not need an outside donor; therefore the treatment is less infectious and convenient. These factors are likely to boost the growth of the market in North America. However, Asia Pacific is expected to show the maximum growth in the forecast period. The demand in this region will be led by countries such as China, India, Malaysia, and Vietnam. The demand is likely to grow as autologous stem cell and non-stem cell based therapies aid in the efficient management of cardiovascular diseases as well. Growing healthcare infrastructure as well as increasing collaboration and acquisition by market players in this region is also expected to help in the growth of the autologous stem cell and non-stem cell based therapies market in the Asia Pacific. For instance in January 2018, Vericel Corporation made a licensing agreement with Innovative Cellular Therapeutics (ICT) for development and distribution of autologous stem cell based therapy products such as MACI, Epicel, ixmyelocel-T and Carticel  in Greater China, South Korea, Singapore, and other countries in the region

Key players in the global autologous stem cell and non-stem cell based therapies market are investing heavily in their research and development activities so as to gain an upper hand in the market. Some of the major players operating in the market are Caladrius Biosciences, Vericel Corporation, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation. 

Key players operating in the market has robust pipeline of autologous stem cell and non-stem cell based therapies, which is expected to drive market over the forecast period. For instance in November 2019, Caladrius Biosciences (previously known NeoStem, Inc) announced positive results of CD34+ cell therapy CLBS16 from the ESCaPE-CMD Trial as a significant advancement in treatment of Coronary Microvascular Dysfunction (CMD), a condition that disproportionately afflicts women.

 

Labels:

Comments

Post a Comment

Popular posts from this blog

Life Sciences BPO Market is Expected to Grow Drastically, Assured By Experts From 2023 To 2028

  The growing cost of drug development is augmenting the growth of the global life sciences BPO market. For instance, according to a study by the Tufts Center for the Study of Drug Development published in the Journal of Health Economics in May 2019, the cost of drug development was US$ 2.6 billion, which included average out-of-pocket costs of US$ 1.4 billion and time costs of US$ 1.2 billion. Also, patent expiration is another key factor propelling the growth of the life sciences BPO market. For instance, the patent for YAZ (drospirenone/ethinylestradiol), which provides an oral contraceptive regimen, is set to expire in 2021. Furthermore, the rising prevalence of chronic disease around the globe is further anticipated to accelerate the growth of the market. North America is projected to lead the global life sciences BPO market due to increasing R&D in cell therapies by key players in the region. For instance, in February 2020, Caribou Biosciences, Inc., a CRISPR genome editin
Post a Comment
Read more

Mixed Reality in Healthcare Market 2022 Global Industry Analysis By Size, Share, Trends and Growth Till 2028

  Mixed Reality technologies help in improving the productivity of healthcare professionals. They are able to work more productively as they are allowed to fully enjoy all the benefits of both worlds. The main use of augmented reality or virtual reality in this regard is related to the treatment and rehabilitation of patients in a medical environment. There are many pharmaceutical companies that are using the technologies to manufacture better medicines and better equipment. Mixed Reality in Healthcare Market - Market Dynamics Growing demand for digitalization in healthcare sector is a major factor contributing to significant growth of mixed reality in healthcare market . Moreover, the market is expected to witness positive growth with rising prevalence of neurological & psychological disorders across the world.
Post a Comment
Read more

Structural Heart Devices Market to develop innovative Mitral Valve Repair Technology

  Structural heart devices Market are medical devices with the ability to pump blood by way of the heart. This device is called the ventricular myocardium, and it is what pumps blood from the heart to the various chambers of the body. The structure that this type of heart device has is very basic - a couple of stacks of cells (or more, depending upon the desired function), and a tubing filled with fluid that can allow for the movement of the cells. This particular construction has allowed these devices to be built so that they can pump blood and create heart attacks and heart failure with much greater efficiency. Lack of skilled personnel and low affordability is expected to restrain growth of the global structural heart devices market during the forecast period. However, the emergence of tissue-engineered heart valves and the advent of percutaneous interventions can offer major business opportunities in the global structural heart devicesmarket . Key players involved in the global
Post a Comment
Read more